Press Release
| April 08, 2019

Q2 Solutions | EA Genomics launches Illumina’s TruSight™ Oncology 500 Tumor Profiling assay services for the analysis of Tumor Mutational Burden

Morrisville, N.C. – April 8, 2019 – Q2 Solutions | EA Genomics launches Illumina’s  TruSight™ Oncology 500 (TSO 500) next-generation sequencing (NGS) assay services for the analysis of key immunotherapy biomarkers: tumor mutational burden (TMB) and microsatellite instability (MSI). The deep investigational power of Illumina’s TSO 500 comprehensive, pan-cancer assay stems from its coverage of 523 cancer hotspot genes, TMB and MSI, while interrogating 1.94Mb of the genome.

“We are very excited about the addition of the Illumina TSO500 assay to our testing portfolio, demonstrating our ongoing commitment to enable oncology clinical research and companion diagnostic development via a comprehensive portfolio of immuno-oncology biomarker tools.” said Kellie Yarnell, Vice President, Genomic Laboratories at Q2 Solutions.

Previously launched immuno-oncology services include exome sequencing based TMB, MSI by PCR, T-cell receptor sequencing and Immune Landscape Signatures assay for the analysis of tumor microenvironment.

“We are very pleased to supply Q2 Solutions with Illumina’s TruSight Oncology 500 assay to enable the company’s translational research customers,” said Garret Hampton, Ph.D., Senior Vice President of Clinical Genomics at Illumina. “We expect that the use of TruSight Oncology 500 will lead to robust biomarker discovery, while also directly supporting oncology-focused therapeutics and companion diagnostic development.”

In addition to its Genomic Center of Excellence in Research Triangle Park, Q2 Solutions | EA Genomics plans to offer the TSO 500 assay in its state-of-the-art genomic service laboratories in Beijing, China and Edinburgh, UK. 

Review our new scientific poster, presented at AACR 2019, highlighting panel-based TMB analysis of matched tumor and plasma specimens using Illumina’s TSO500 NGS assay.


About Q2 Solutions
Q2 Solutions is a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. With a relentless focus on quality and innovation, Q2 Solutions uses its global experience and scientific expertise to transform science and data into actionable medical insights that help customers improve human health. Q2 Solutions’ industry-leading genomic and bioinformatics services provide customers with DNA and RNA sequencing and other testing as well as the ability to mine data for invaluable insights for drug discovery, precision medicine and clinical development. Q2 Solutions | EA Genomics works with clients, using a wide array of technology platforms, to ensure maximum efficiency and quality delivery for every study. A joint venture of IQVIA (formerly QuintilesIMS) and Quest Diagnostics, Q2 Solutions combines the best of each parent organization’s clinical trials laboratory services capabilities to fulfill its mission of treating each sample as if a life depends on it. To learn more, visit www.q2labsolutions.com.